ANRO
Alto Neuroscience, Inc.
$26.48
-1.16 (-4.20%)
At close · Jul 10
Market Cap
$929.29M
Shares
35,093,940
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.48
Open$27.20
Day$24.81–27.63
52W$2.50–28.44
Avg vol 30d541K
Short int2.4M · 6.9% float · 3.0d
Short vol72%
Last earningsMar 16, 2026
DataFeb 2024–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Oct 17, 2026
Est · unconfirmed
· in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+48%
above
Price vs 50-day avg
+15%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+35%
trailing
6-month return
+56%
trailing
YTD return
+49%
this year
Relative strength
+47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
3 of 111 funds reported for Jun 30 · net +8.6K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.87% of float · ▲ +48.6% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 2-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
+12%
Y/Y
Free cash flow
$-51.8M
Balance sheet
$166.2M
net cash
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+48%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $23 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
3 of 111 funds reported for Jun 30 · net +8.6K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.87% of float · ▲ +48.6% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $26 · 92%
52-wk high $28
vs 200-day avg +48%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cognitively impaired subgroup (n) | 59 | Q1 FY2026 | — |
| Overall study population (n) | 83 | Q1 FY2026 | — |
| Patients screened out of the ALTO-100 trial through sponsor eligibility review | 11% | Q1 FY2026 | — |
| Patients screened out of the ALTO-300 trial through sponsor eligibility review | 13% | Q1 FY2026 | — |
| Phase 2b trial enrollment (approximate number of adults with TRD) | 178 | Q1 FY2026 | — |
| PK samples demonstrating expected drug concentration levels | 97% | Q1 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANRO
this stock
Alto Neuroscience, Inc.
|
$929.29M | +48.8% | — | — | 6.9% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANRO | +6.9% | +34.6% | +55.6% | +0.3% | +48.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +5.5% | +30.5% | +46.5% | -0.8% | +38.1% |